Nursing Elites

1. A client with peptic ulcer disease is prescribed omeprazole. Which finding should indicate to the nurse that the medication is effective?

• A. Relief of headache
• B. Relief of nausea
• C. Relief of abdominal pain
• D. Relief of heartburn

Correct answer: C

Rationale: Relief of abdominal pain is a key indicator of omeprazole effectively treating peptic ulcer disease. Omeprazole works by reducing stomach acid production, which helps alleviate abdominal pain associated with peptic ulcers. While relief of other symptoms like headache, nausea, and heartburn may also occur, the primary therapeutic goal of omeprazole in peptic ulcer disease is to reduce abdominal pain caused by gastric irritation. Therefore, the relief of abdominal pain is the most significant finding to indicate the effectiveness of omeprazole in this context. Choices A, B, and D may improve as a result of decreased stomach acid production, but they are not as specific or central to the therapeutic goal of treating peptic ulcer disease as the relief of abdominal pain.

2. A client taking nitroglycerin (Nitrostat) for angina asks the nurse to explain possible side effects. What should NOT be included in client teaching?

• A. Reflex tachycardia
• B. Dizziness
• C. Hyponatremia
• D. Hypotension

Correct answer: C

Rationale: Hyponatremia is not a common side effect associated with nitroglycerin use. Nitroglycerin typically causes side effects such as reflex tachycardia, dizziness, and hypotension due to its vasodilatory effects. Therefore, it is important for the nurse to educate the client about these potential side effects to promote understanding and appropriate management.

3. What is the expected pharmacological action of propranolol?

• A. Block stimulation of beta1 receptors
• B. Alter water and electrolyte transport in the large intestine
• C. Block stimulation of beta2 receptors
• D. Both A and C are correct

Correct answer: D

Rationale: Propranolol exerts its pharmacological action by blocking stimulation of both beta1 and beta2 receptors. By doing so, it leads to decreased heart rate and blood pressure. Therefore, both options A and C are correct as propranolol affects both types of beta receptors. Choice B is incorrect as propranolol does not alter water and electrolyte transport in the large intestine.

4. What is the pharmacological action of metformin?

• A. Blocks stimulation of beta1 and beta2.
• B. Blocks vasoconstriction and aldosterone.
• C. Acts at many levels in the CNS to produce an anxiolytic effect.
• D. Decreases hepatic glucose production.

Correct answer: D

Rationale: The correct answer is D: Decreases hepatic glucose production. Metformin's primary pharmacological action is to decrease hepatic glucose production, leading to lower blood sugar levels and improved insulin sensitivity in the liver. Choices A, B, and C are incorrect because metformin does not block stimulation of beta1 and beta2 receptors, vasoconstriction, aldosterone, or act in the CNS to produce an anxiolytic effect. Therefore, these options are not reflective of metformin's mechanism of action.

5. A healthcare professional is caring for a client who is prescribed Metformin. Which of the following laboratory values should the healthcare professional monitor to assess for potential adverse effects?

• A. Blood glucose
• B. Creatine kinase
• C. Hemoglobin A1c
• D. Serum creatinine

Correct answer: D

Rationale: Corrected Rationale: Metformin can lead to lactic acidosis, especially in individuals with impaired renal function. Monitoring the client's serum creatinine levels is crucial to assess kidney function because Metformin is eliminated by the kidneys, and impaired renal function can increase the risk of adverse effects. Monitoring blood glucose levels is essential for assessing the effectiveness of Metformin in managing diabetes but is not directly related to potential adverse effects of Metformin. Creatine kinase is not typically monitored in relation to Metformin therapy. Hemoglobin A1c is used to assess long-term glucose control in diabetes but is not specific for monitoring Metformin adverse effects.

Similar Questions